The health of Elixinol Global (ASX:EXL) doesn’t tie directly to the medical cannabis market in Australia, but it does offer a clearer picture on the progress of this sector.

The company offers labelled products, along with bulk and wholesale hemp-derived cannabidiol (CBD), around the world. Its offerings have a variety of health- and wellness-related uses.


Though it’s based in Australia, Elixinol operates heavily in the US, selling hemp-derived CBD products.

The US hemp industry has become attractive for CBD-focused companies, thanks in large part to regulatory moves that have changed how the country’s federal government views hemp.

In an exclusive interview with the Investing News Network (INN) during the recent MJBizCon event in Las Vegas, Nevada, Leif Harrison, CEO of the American division for Elixinol, explained that due to the global nature of the marijuana industry, potential investors are not deterred by the company’s ASX listing.

The executive added that although marijuana and hemp investment have stuck closer to the Canadian capital markets, US investors interested in the cannabis plant have also seen their horizons expanded.

“This doesn’t feel like (a) traditional US homegrown public entity … I don’t think it surprises anybody at this point,” Harrison said.

The executive added that, in his estimation, Elixinol’s US assets account for a leading portion of the company’s revenue. As such, it falls on them to support the firm’s expansion plans. And because the firm has operations worldwide it must also keep communication open to maintain its direction.

The health of Elixinol Global: Challenges in Japan

A crack in this system showed last year for the company’s division in Japan. In October, Elixinol told investors it had discovered a breach in its compliance standards out of Elixinol Japan.

The issue, which caused the company to launch an internal investigation, was due to the sourcing of CBD used in its products.

“The non-compliance relates to the strict requirements in Japan on sourcing CBD from only hemp stalk and seed,” the company said in a statement.

Harrison explained to INN that the international ventures of the firm are more likely to get fed hemp-derived CBD products from the US. This led to a mismatch in the regulation standards since the company makes its products from flowers and leaves.

“Until we can set up local production based on local rules, then we’re out of that market until we get back in the right way,” Harrison said.

In December, the parent company confirmed it had sold over half of its stake in Elixinol Japan.

“We have made an important decision to move to a licensing model for Japan and to press ahead with our growth priorities in our key markets,” Andrew Duff, chairman of Elixinol, said at the time.

The health of Elixinol Global: Investor takeaway

So far in 2020, Elixinol has seen the value of its shares rise steadily as it tries to regroup from a difficult 2019 for itself and the financial space at large. During the year, the firm saw its value drop by nearly 80 percent on the ASX.

Shares of Elixinol had bounced back by over 20 percent in value by the start of February 2020.

Despite the challenges presented to the global cannabis investment market last year, experts agree 2020 may be poised to offer alternative takes on the market with a bigger spotlight on investors.

Cameron Bell, an analyst with Canaccord Genuity Australia, issued a note to investors highlighting how investors’ concerns about the industry may be easing up, including in the burgeoning Australian market.

“The strength has been partially led by investor sentiment in offshore markets, as some key concerns have eased while expectations for demand growth remain very high and access to funding improves,” Bell wrote in his note.

Elixinol is a leading name in Canaccord’s own Australian Cannabis Index based on its market cap.

For more on Elixinol, listen below to INN’s interview with Joy Beckerman, the company’s regulatory officer and industry liaison, at last year’s MJBizConINT’L event in Toronto, Ontario.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB) (TSX: ACB), and HEXO Corp. (NYSE: HEXO)

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.

In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.

Keep reading... Show less

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press releases dated July 21, 2020 and July 31, 2020, the Company proposes to amend the exercise price of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

The Company had initially proposed a lower amended price, but that proposal was not approved by the TSX Venture Exchange (“Exchange“), however, the Exchange indicated that a $0.10 exercise price, may be more acceptable. Accordingly, the proposed amendment remains subject to Exchange approval.

Keep reading... Show less

Issuance of U.S. Patent No. 10,851,077 covering methods for extracting and concentrating cannabinoids using ultrasound-enhanced solvent extraction bolsters World Class’ intellectual patent portfolio

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announced the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10,851,077 on December 1, 2020 in relation to the Company’s methods for extracting and concentrating cannabinoids and other target compounds from cannabis using ultrasound-enhanced solvent extraction

Keep reading... Show less